Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia
Status:
Active, not recruiting
Trial end date:
2021-12-20
Target enrollment:
Participant gender:
Summary
In this study, the investigators seek to determine whether decitabine therapy can improve
outcomes, specifically overall survival this selected subset of acute myeloid leukemia (AML)
patients with the poorest prognosis based on refractoriness to induction treatment and high
risk genetic mutations.
Phase:
Phase 2
Details
Lead Sponsor:
Washington University School of Medicine
Collaborators:
Janssen Pharmaceuticals National Cancer Institute (NCI) National Institutes of Health (NIH)